ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Geriatric Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,112Medicare Part D Prescriptions Filled, Including Refills

Rank: 8 out of 29

$654K Total Retail Price of All Prescriptions

Rank: 8 out of 29

660 Patients Receiving at Least One Drug in Part D
99%Patients 65 Years and Older
24% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Arkansas
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 660 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

12% of this provider’s 660 patients filled at least one prescription for a schedule three drug, compared to an average of 13%.

Risky Drugs to Seniors

1% of this provider’s 11,022 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$59 was the average price of a prescription from this provider, compared to $52 among peers.

Prescriptions per Patient

17 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Arkansas
LEVOTHYROXINE SODIUM 856 837 1 1
LISINOPRIL 470 468 2 2
AMLODIPINE BESYLATE 465 450 3 5
SIMVASTATIN 425 425 4 4
DONEPEZIL HCL 350 350 5 9
HYDROCODONE-ACETAMINOPHEN 337 337 S3 6 7
CITALOPRAM HBR 331 331 7 11
OMEPRAZOLE 330 314 8 8
NAMENDA 248 248 9 12
ATENOLOL 222 222 10 23
TRAMADOL HCL 216 214 11 24
PRAVASTATIN SODIUM 189 189 12 18
GABAPENTIN 185 185 13 10
HYDROCHLOROTHIAZIDE 184 180 14 20
TRAZODONE HCL 177 177 15 22
ATORVASTATIN CALCIUM 176 176 16 25
FUROSEMIDE 169 167 17 3
POTASSIUM CHLORIDE 168 168 18 6
WARFARIN SODIUM 149 149 19 14
CARVEDILOL 142 142 20 27
METFORMIN HCL 134 123 21 19
METOPROLOL TARTRATE 119 119 22 15
METOPROLOL SUCCINATE 116 116 23 16
LOVASTATIN 116 114 23 101
ESCITALOPRAM OXALATE 110 110 25 37
ZOLPIDEM TARTRATE 109 109 26 30
SYNTHROID 109 109 26 52
CLOPIDOGREL 104 104 28 33
PLAVIX 91 91 29 51
ENALAPRIL MALEATE 87 87 30 72
CARBIDOPA-LEVODOPA 78 78 31 42
SERTRALINE HCL 77 77 32 17
LISINOPRIL-HYDROCHLOROTHIAZIDE 76 76 33 64
TRIAMTERENE-HCTZ 74 74 34 48
CRESTOR 73 72 35 62
ISOSORBIDE MONONITRATE ER 71 71 36 44
LOSARTAN POTASSIUM 70 70 37 28
MIRTAZAPINE 69 69 38 13
CALCITONIN-SALMON 69 69 38 135
DIOVAN 68 68 40 35
AGGRENOX 67 67 41 79
GLIPIZIDE 67 67 41 50
FENTANYL 62 62 S2 43 76
DIGOXIN 60 60 44 34
BENAZEPRIL HCL 56 52 45 83
PAROXETINE HCL 50 50 46 68
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 27, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.